Skip to Main Content

Author Details

Xiaohu Zhang
National Center for Advancing Translational Sciences
2003
52
23
PMIDPaper TitleJournal TitlePublished Year
36883564mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer.JCI Insight2023
37627061Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.Cancers (Basel)2023
37353483Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.Nat Commun2023
37054779Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma.J Control Release2023
37380628A landscape of response to drug combinations in non-small cell lung cancer.Nat Commun2023
37140427CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations.Cancer Res2023
37095531High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.J Exp Clin Cancer Res2023
37356470Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.Cancer Lett2023
34264955Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.PLoS One2021
33742123Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer.Oncogene2021
33848478Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.Cancer Cell2021
34378323Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis.EMBO Mol Med2021
34778802Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.Blood Cancer Discov2021
32259323Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.Genes Chromosomes Cancer2020
32998994Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.Cancer Res2020
32642733KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.Neurooncol Adv2020
32149729Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.J Clin Invest2020
31446060High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis.Papillomavirus Res2019
31748226Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening.Sci Transl Med2019
31484791Overcoming adaptive therapy resistance in AML by targeting immune response pathways.Sci Transl Med2019
29487419Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.Oncogene2018
29973406MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.Sci Transl Med2018
29893754Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.Sci Data2018
30467317High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.Sci Rep2018
28899971Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.Clin Cancer Res2017
28460635Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.J Transl Med2017
28446439PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.Cancer Discov2017
26811457Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.Proc Natl Acad Sci U S A2016
27883049mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening.Sci Rep2016
27906188Large-scale pharmacological profiling of 3D tumor models of cancer cells.Cell Death Dis2016
27846392A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.Cancer Cell2016
27553366Cancer network activity associated with therapeutic response and synergism.Genome Med2016
27313698Cryptotanshinone targets tumor-initiating cells through down-regulation of stemness genes expression.Oncol Lett2016
27058666RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription.Cell2016
27112173Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens.J Biomol Screen2016
23592398Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells.Stem Cells2013
24772452Genomic Analysis of Invasive Human Bone Marrow Derived Mesenchymal Stem Cells.J Bone Marrow Res2013
23462327The differentiation of pancreatic tumor-initiating cells by vitronectin can be blocked by cilengitide.Pancreas2013
22206861The role of upregulated miRNAs and the identification of novel mRNA targets in prostatospheres.Genomics2012
21633318Increased expression of DNA repair genes in invasive human pancreatic cancer cells.Pancreas2011
20500816Genomic profiling of tumor initiating prostatospheres.BMC Genomics2010
20929579Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells.Mol Cancer2010
19221883Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature.Clin Exp Metastasis2009
17785586Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP.Blood2007
17157789Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.Cancer Cell2006
15655377Nuclear receptors as negative modulators of STAT3 in multiple myeloma.Cell Cycle2005
14702633Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor.Nat Med2004
16293210Transcriptional crosstalk between nuclear receptors and cytokine signal transduction pathways in immunity.Cell Mol Immunol2004
15467434NF-kappaB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFkappaB regulatory site in autocrine human multiple myeloma cells.Cancer Biol Ther2004
15389813Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells.Prostate2004
  • 1 - 50 of 52

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 2
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Rahul K Kollipara
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 5
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 1
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 0
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 1
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 0
Nehad M Alajez
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation
Career Start Year 2004
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 7
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 1
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2002
Number of shared co-authors 1
Yuelin J Zhu
National Cancer Institute, National Institutes of Health
Career Start Year 2002
Number of shared co-authors 14
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 0
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Kristiina Iljin
VTT Technical Research Centre of Finland Ltd
Career Start Year 1999
Number of shared co-authors 2
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 0
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 2
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 2
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 0
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 3
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 0
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 3
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 1
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 1
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 3

Collaborators

Craig J Thomas
Center for Cancer Research, National Cancer Institute
Co-authored papers 32
Marc Ferrer
National Institutes of Health, National Center for Advancing Translational Sciences
Co-authored papers 19
Rajarshi Guha
Vertex Pharmaceuticals
Co-authored papers 19
Michele Ceribelli
National Center for Advancing Translational Sciences
Co-authored papers 9
Sam Michael
National Center for Advancing Translational Sciences, National Institutes of Health
Co-authored papers 6
Yves Pommier
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Jun S Wei
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Javed Khan
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Jack F Shern
Co-authored papers 3
William Marston Linehan
Co-authored papers 2
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Young K Song
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Maria J Merino
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Arnulfo Mendoza
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Justin Guinney
University of Washington
Co-authored papers 2
Jaishri O Blakeley
Johns Hopkins University
Co-authored papers 2
Christopher J Ricketts
Co-authored papers 2
Ettore Appella
Co-authored papers 2
Louis M Staudt
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Beverly A Mock
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Darawalee Wangsa
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Thomas Ried
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Danny Wangsa
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 2
Andrew T Girvin
Co-authored papers 1
Holger Heyn
Barcelona Institute of Science and Technology, Spain Universitat Pompeu Fabra
Co-authored papers 1
Augustin Luna
Harvard Medical School
Co-authored papers 1
Angela Tam
Co-authored papers 1
William C Reinhold
Center for Cancer Research, National Cancer Institute
Co-authored papers 1
Vivek Shukla
Chalmers University of Technology
Co-authored papers 1
Release 1.2